Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.
about
Targeting folate receptor alpha for cancer treatmentProfile of farletuzumab and its potential in the treatment of solid tumorsPrecision targeted therapy of ovarian cancerNew perspectives on targeted therapy in ovarian cancerEvidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerFolic acid tagged nanoceria as a novel therapeutic agent in ovarian cancerEvaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.Early detection biomarkers for ovarian cancer.Role of farletuzumab in epithelial ovarian carcinoma.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Therapeutic targets and new directions for antibodies developed for ovarian cancer.Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsTargeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide.A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy.Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.Clinical trials and future potential of targeted therapy for ovarian cancer.The current state of pemetrexed in ovarian cancer.Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.Synthesis and biological evaluation of (68) Ga-labeled Pteroyl-Lys conjugates for folate receptor-targeted tumor imaging.Nuclear medicine for imaging of epithelial ovarian cancer.Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.Intraperitoneal immunotherapy: historical perspectives and modern therapy.High folic acid diet enhances tumour growth in PyMT-induced breast cancer.Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.Advances in targeting the folate receptor in the treatment/imaging of cancers.One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer
P2860
Q26744215-D2456B38-1D4A-4DA8-9E3A-4DAB409E74F9Q26750431-3387FD47-1CD2-4183-8154-827FB5399910Q28078658-7933A330-3DF1-40F2-85F2-CE17140DC2FFQ28082524-94955385-D61E-4589-92F2-5AB9DD85760AQ34687073-83FBA48D-5D81-486E-BB15-4BC99F71FA10Q35659378-0BECA151-97DA-4F02-B825-25B38A5A882AQ35958147-4E8C104D-CD3B-43C7-B135-C087932A4C6CQ36093220-F3B2DB5C-314E-4C81-9709-7B224FEC84A2Q36508941-01152A2B-B6D4-4FD6-8F95-84F2586BD1FCQ36520143-BEC52516-15B9-4CE3-9E41-F1A975211E01Q36622914-4F3BF58E-8CF6-4083-8194-3E19D4FFB2ADQ37220528-A2E8B5C2-BA02-4DA9-9F3D-EF2C4C968510Q37397674-14E38762-2B07-40B1-9701-C4FFBE5E5231Q37447340-46ED2F64-2021-4C68-A78E-7ACB430EE851Q37567078-2E7736DA-FFD1-4113-9DA8-7A5392F54014Q37588429-CBC360D0-7422-4B95-962A-D88599FFC5ECQ37685630-2182E721-070D-45E0-A527-9E4C8C38395BQ38038489-6809B019-A511-414F-89C2-094B60353ABDQ38125259-9A05FD1B-E724-4E8D-836D-E9CCEA0CE5F3Q38205273-4CCCA0D8-DB2C-4AAE-A338-448948B1246FQ38248418-EC28E53F-0052-4BE9-99F6-926AF3549239Q38309549-F9ABE105-074C-42BD-94DF-C4DAE0FAFD67Q38524502-2CA7CB42-744E-4123-B5EB-EE210DB23185Q38718741-0547D9AD-4093-4FBC-9FD3-64B6DCB34718Q38763433-1465231A-4C61-49EC-B363-960EB877FB36Q38777588-02C9413A-D04E-417D-B3A4-2E29D944FDC3Q38995020-C754A020-4943-4BD0-BEA7-6D020E4C0A94Q39005211-07B3D9AF-A350-4DA5-A285-E7CE3B78AF1FQ40353665-F3299F27-FBD0-4CFD-BFFB-5E78C8FC9826Q44693364-33C96FCD-30EF-4C5F-A30C-E69E3F9B17A7Q47861842-3ED98A9E-FDB5-485E-8B09-9B6107E8EF9FQ49869601-F082CEC0-9661-4794-A3B2-EA4654846B1FQ55315165-4F946CF8-B367-4107-B668-9C4BE5D09CA9Q59134002-BEE8801D-20F4-4966-9F16-A9BABAE12501
P2860
Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Serous ovarian carcinoma patie ...... and cytotoxic chemo-response.
@en
Serous ovarian carcinoma patie ...... and cytotoxic chemo-response.
@nl
type
label
Serous ovarian carcinoma patie ...... and cytotoxic chemo-response.
@en
Serous ovarian carcinoma patie ...... and cytotoxic chemo-response.
@nl
prefLabel
Serous ovarian carcinoma patie ...... and cytotoxic chemo-response.
@en
Serous ovarian carcinoma patie ...... and cytotoxic chemo-response.
@nl
P2093
P2860
P1433
P1476
Serous ovarian carcinoma patie ...... l and cytotoxic chemo-response
@en
P2093
Chang-Yao Hsieh
Chi-An Chen
Chia-Yen Huang
Han-Wei Lin
Ming-Cheng Chang
Yu-Li Chen
P2860
P304
P356
10.1016/J.MOLONC.2011.11.010
P577
2011-12-20T00:00:00Z